Paul Timpson — ASN Events

Paul Timpson

Garvan Institute and The Kinghorn Cancer Centre, NSW, Australia

  • This delegate is presenting an abstract at this event.
Paul completed his PhD with Prof Margaret Frame at the Beatson Institute for Cancer Research, UK in 2002 where he assessed the interplay between Src family kinases and the actin cytoskeleton during cancer cell invasion, focusing on the role of Rho family GTPases. He then moved to the Garvan Institute in 2003 to work with Professor Roger Daly investigating the role of the actin-binding protein cortactin in growth factor receptor trafficking in breast cancer and head and neck cancers. Paul was awarded an AstraZeneca Postdoctoral Research Fellowship allowing him to return to the UK in 2007, to work with Professor Kurt Anderson in collaboration with AstraZeneca Advanced Technology Laboratories. This ongoing work has focused upon the development of novel multi-disciplinary live imaging techniques to investigate molecular dynamics of cancer cells in vivo. Returning to Australia to establish a research group in November 2012 within the Cancer Program, Paul aims to understand pancreatic cancer in the context of the surrounding environment using cutting edge imaging technology. Pinpointing the molecular drivers of cancer progression and the environmental cues that cause resistance to current systemic therapy are the focus of his research.
Presentations this author is a contributor to:

Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor and chemotherapeutic efficacy in pancreatic cancer (#268)

5:35 PM
Victoria M Tyma
Poster Session 2

Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq (#266)

5:35 PM
Michael Trpceski
Poster Session 2

Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer (#153)

5:40 PM
Katie Gordon
Welcome Reception & Poster Session 1

Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response (#235)

5:35 PM
Brooke Pereira
Poster Session 2

Pancreatic cancer secretome reveals PCSK9 as a co-target to sensitise tumours to chemotherapy and reduce metastasis (#244)

5:35 PM
Shona Ritchie
Poster Session 2

Targeting the NPY/NPY1R signaling axis impairs metastasis and tissue wasting in pancreatic cancer (#159)

5:40 PM
David Herrmann
Welcome Reception & Poster Session 1

Identifying and targeting treatment response mechanisms to improve Gemcitabine/Abraxane performance in Patient-Derived Models of Pancreatic Cancer (#263)

5:35 PM
Alice Tran
Poster Session 2

Targeting subcellular JNK activity in pancreatic cancer (#123)

5:40 PM
Antonia Cadell
Welcome Reception & Poster Session 1

Detecting changes in the tumour microenvironment and CAR T infiltration following chemotherapeutic priming using intravital imaging (#142)

5:40 PM
Marija Dinevska
Welcome Reception & Poster Session 1